At a glance
- Originator Meiji Seika Kaisha; Nonindustrial source; Suntory
- Class Antineoplastics
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 2001 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 19 Jun 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 19 Jun 2001 Preclinical development for Cancer in USA (Unknown route)